Eligible patients were diagnosed with favourable-risk prostate cancer (Gleason 6 and prostate-specific antigen [PSA] <10) within the previous 12 months. Out of the 296 registered patients, 273 were randomized between systematic 12-core biopsy and an MRI, with targeted and systematic biopsies, done between six and 13 months after the initial biopsy. There were no differences between treatment arms in terms of stratum, demographics, tumour characteristics, or prior treatments.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
If targeted biopsies only were performed in men with a PIRADS 3-5 target, 19/127 (15%) of patients would have been upgraded and 10/137 (7.3%, 95% CI 3.6-13%) would have been missed. If targeted and systemic biopsies were performed only in those with a PIRADS 3-5 lesion, clinically significant cancer would have missed in 3.6%.
In summary, no significant difference was observed in the rate of upgrading between confirmatory biopsy with TRUS compared with MRI-guided targeted biopsy. No secondary outcome was statistically significant. Performing confirmatory targeted biopsy only in men with a PI-RADS lesion ≥3 would identify 89% of Gleason 7 or greater cancers. Doing only targeted biopsies missed clinically significant cancers in 7% of patients. MRI with targeted biopsies will identify most, but not all men with higher Gleason grade.
Presented By: Laurence H. Klotz, MD, University of Toronto, Toronto, Ontario, Canada
Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre Twitter: @GoldbergHanan at the 72nd Canadian Urological Association Annual Meeting - June 24 - 27, 2017 - Toronto, Ontario, Canada